Kymab secures $100 million Series C funding
The funds will enable Kymab to advance its proprietary pipeline…
1 December 2016 | By Niamh Louise Marriott, Digital Editor
The funds will enable Kymab to advance its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies, with clinical development in 2017...